Phendimetrazine

Summary

Phendimetrazine (CHEMBL1615439) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 1
• Chemistry: 191.27 Da · C12H17NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1615439
Name	Phendimetrazine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	30487
Molecular formula	C12H17NO
Molecular weight	191.27
InChIKey	MFOCDFTXLCYLKU-CMPLNLGQSA-N

SMILES: C[C@H]1[C@@H](OCCN1C)C2=CC=CC=C2

IUPAC name: (2S,3S)-3,4-dimethyl-2-phenylmorpholine

Also known as: Fendimetrazina, NSC-169187, Phendimetrazine, phendimetrazine, PHENDIMETRAZINE

Parent form; salt/anhydrous children: CHEMBL2062163

Patent coverage: 171 distinct patent families (494 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: 5-hydroxytryptamine receptor 1A.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02522325	PHASE1	COMPLETED	Reinforcing Effects of Cocaine During Phendimetrazine Maintenance

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).